




# Prognosis of immune checkpoint inhibitors-induced myocarditis: a case series

Cyrille Coustal,<sup>1</sup> Juliette Vanoverschelde,<sup>2</sup> Xavier Quantin,<sup>3</sup> Candice Lesage,<sup>4</sup> Jean-Marie Michot,<sup>5</sup> Ariane Lappara,<sup>6</sup> Stephane Ederhy ,<sup>7</sup> Eric Assenat,<sup>8</sup> Maxime Faure,<sup>9</sup> Nahema Issa,<sup>10</sup> Olivier Lambotte,<sup>11</sup> Mathieu Puyade ,<sup>12,13</sup> Olivier Dereure,<sup>4</sup> Diego Tosi,<sup>14</sup> Patricia Rullier,<sup>1</sup> Isabelle Serre,<sup>15</sup> Romaric Larcher,<sup>16</sup> Kada Klouche,<sup>16</sup> Gérald Chanques,<sup>17</sup> Hélène Vernhet-Kovacsik,<sup>2</sup> Jean-Luc Faillie ,<sup>18</sup> Audrey Agullo,<sup>19</sup> François Roubille,<sup>19</sup> Philippe Guilpain,<sup>1,20</sup> Alexandre Thibault Jacques Maria <sup>1,20</sup>

**To cite:** Coustal C, Vanoverschelde J, Quantin X, *et al.* Prognosis of immune checkpoint inhibitors-induced myocarditis: a case series. *Journal for ImmunoTherapy of Cancer* 2023;**11**:e004792. doi:10.1136/jitc-2022-004792

► Additional supplemental material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/jitc-2022-004792>).

JV and XQ contributed equally.

Accepted 23 May 2022



© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

## Correspondence to

Dr Alexandre Thibault Jacques Maria;  
alexandremaria@hotmail.fr

## ABSTRACT

**Background** Immune checkpoint inhibitors (ICI) have transformed cancer treatment over the last decade. Alongside this therapeutic improvement, a new variety of side effects has emerged, called immune-related adverse events (irAEs), potentially affecting any organ. Among these irAEs, myocarditis is rare but life-threatening.

**Methods** We conducted a multicenter cross-sectional retrospective study with the aim of better characterizing ICI-related myocarditis. Myocarditis diagnosis was based on the recent consensus statement of the International Cardio-Oncology Society.

**Results** Twenty-nine patients were identified, from six different referral centers. Most patients (55%) were treated using anti-programmed-death 1, rather than ICI combination (35%) or anti-programmed-death-ligand 1 (10%). Transthoracic echocardiography was abnormal in 52% of them, and cardiac magnetic resonance showed abnormal features in 14/24 patients (58%). Eleven patients (38%) were classified as severe. Compared with other patients, they had more frequently pre-existing systemic autoimmune disease (45% vs 6%,  $p=0.018$ ), higher troponin level on admission (42-fold the upper limit vs 3.55-fold,  $p=0.001$ ), and exhibited anti-acetylcholine receptor autoantibodies ( $p=0.001$ ). Seven patients (24%) had myocarditis-related death, and eight more patients died from cancer progression during follow-up. Twenty-eight patients received glucocorticoids, 10 underwent plasma exchanges, 8 received intravenous immunoglobulins, and 5 other immunosuppressants. ICI rechallenge was performed in six patients, with only one myocarditis relapse.

**Discussion** The management of ICI-related myocarditis may be challenging and requires a multidisciplinary approach. Prognostic features are herein described and may help to allow ICI rechallenge for some patients with smoldering presentation, after an accurate evaluation of benefit–risk balance.

## BACKGROUND

Cancer therapy has profoundly evolved over the past decades, with harnessing of

## WHAT IS ALREADY KNOWN ON THIS TOPIC

⇒ Immune checkpoint inhibitors (ICI)-related myocarditis is a rare and life-threatening adverse event, with little data about predictors of outcome.

## WHAT THIS STUDY ADDS

⇒ Through a series of 29 ICI-related myocarditis we report an overall lower mortality than initially described and evidence of some prognostic factors for worse outcome, such as a pre-existing autoimmune disease or a higher troponin level on admission. For the first time, we also report safe ICI rechallenge after myocarditis in six patients with a long follow-up.

## HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

⇒ Early detection of ICI-related myocarditis through a multidisciplinary approach may improve the management of oncology patients. Identification of prognostic factors for severity may also allow ICI rechallenge in some cases, after an accurate evaluation of benefit–risk balance.

antitumor immunity as a new tool in the treatment landscape. Ipilimumab was the first approved immune checkpoint inhibitor (ICI) in 2011, and since, seven drugs have been Food and Drug Administration approved, targeting cytotoxic T-lymphocyte-associated antigen-4 or programmed-cell death (ligand)-1 (PD(L)-1).<sup>1</sup> Outcomes of patients improved in different types of cancer, and the indications for these drugs are extending fast.<sup>1,2</sup> Yet, they are responsible for multiple side effects, driven by unregulated immune system activation, commonly termed as ‘immune-related adverse events’ (irAEs). Some are frequent and have been well characterized such as colitis, hepatitis, or thyroiditis.<sup>3,4</sup> In that context, cardiovascular

adverse events are rare, but of rising concern, especially myocarditis.<sup>5,6</sup> More and more cases are described in the literature, with a mortality rate up to 50%.<sup>6</sup> The difficulties are numerous, including the diagnosis of such irAE, as the gold-standard is still endomyocardial biopsy, which may be difficult to perform. Moreover, international guidelines on ICI-related myocarditis management remain vague: beyond ICI discontinuation and the use of steroids, data are limited. Plus, ICI discontinuation can be a loss of chance for the patient, and we lack data about ICI rechallenge.<sup>7</sup> This multicenter case series describes the clinical manifestations, management, and outcomes of patients with ICI-related myocarditis

## PATIENTS AND METHODS

We conducted a multicenter retrospective cross-sectional study. We identified consecutive patients in Montpellier University Hospital and Montpellier Institute of Cancer from July 2019 to November 2020 through a regional specific network dedicated to ICI-related toxicities (ToxImmun referral center), led by internists, oncologists, and pharmacovigilance department. This network allows a rather comprehensive identification of cases together with accurate data collection. We also identified cases from four other reference centers (ie, Gustave Roussy Institute, Kremlin-Bicêtre University Hospital, Bordeaux University Hospital and Poitiers University Hospital) by a call for observations through national networks. In the context of ICI therapy, myocarditis definition was based on the recent consensus statement published by the International Cardio-Oncology Society (IC-OS)<sup>8</sup> (online supplemental table S1). Patients were further classified as possible/probable/confirmed myocarditis like proposed by Bonaca *et al*<sup>9</sup> (online supplemental table S1). Alternate diagnosis for troponin elevation (pulmonary embolism, myocardial infarction, pericarditis, ...) were excluded. Medical records were reviewed for demographic data, personal medical history, previous oncologic and non-oncologic treatments, clinical data (signs and symptoms, time to myocarditis occurrence), laboratory and imaging data (ECG, high-sensitivity (HS) troponin (T or I), transthoracic echocardiography (TTE), cardiac magnetic resonance (CMR) and endomyocardial biopsies (EMB)). For the sake of standardization, HS-troponin values were normalized according to each laboratory upper limit reference. CMR diagnosis was based on modified Lake Louise criteria.<sup>10</sup> Day 0 was assigned as the day when the myocarditis was suspected (first clinical or paraclinical sign). Myocarditis severity was graded according to Common Toxicity Criteria for Adverse Events (CTCAE V.5.0) and IC-OS consensus statement on cardiovascular toxicities of cancer therapies (online supplemental table S1).

Quantitative variables were reported as medians (range) and compared using Mann-Whitney non-parametric tests. Qualitative variables were expressed as percentage and compared with Fisher's exact test. A receiver operating

characteristic (ROC) curve was performed to assess troponin diagnostic abilities to distinguish severe presentations. Statistical differences were considered significant if  $p < 0.05$ . All statistical analysis was made using Prism 8.0.2 (GraphPad Software, San Diego, California, USA).

## RESULTS

We included 29 patients from six different care referral centers including 12 definite, 10 probable, and 7 possible myocarditis, with a median age of 68 (32–83) years (see online supplemental figure S1: flow-chart, [table 1](#), and online supplemental table S2 for individual details). Twenty-four patients (83%) had at least one cardiovascular risk factor, and 13 (45%) had pre-existing underlying autoimmunity (defined autoimmune condition or isolated autoantibodies). Ten patients (34%) received ICI for the treatment of non-small cell lung cancer, 8 (28%) for melanoma, 4 (14%) for renal or bladder carcinoma. Twenty-four out of 29 patients (83%) were at metastatic stage and 26 out of 29 (90%) had previous cancer treatment. Nineteen patients (65%) were treated with anti-PD-(L)1 monotherapy, others with combi-therapy. Myocarditis occurred in a median time of 39 days (IQR 39.5 days) ([figure 1](#)). Patients presented with cardiac symptoms most of the time (83%), mainly dyspnea ([table 1](#)). Median admission troponin was 5.35-fold (range: 1.57–456) the upper limit. The ECG was abnormal in 20 (69%) patients (nine arrhythmia; nine repolarization abnormalities; six conduction trouble). TTE showed decreased left ventricular ejection fraction (LVEF) in 10 out of 27 (37%) patients. Global longitudinal strain was assessed in eight patients with normal LVEF and altered in four of them (50%). Twenty-five patients underwent CMR, 16 (55%) of them showing late gadolinium enhancement. T2 Short Tau Inversion Recovery (STIR) edema was positive in 7/22 (32%), whereas T1-mapping and T2-mapping were positive in respectively 8/13 (62%) and 6/10 (60%) patients. Eighteen patients had suggestive CMR (ie, isolated T1 or T2 criterion, wall motion abnormality and/or pericarditis) and 10 out of 25 fulfilled modified Lake Louise criteria for myocarditis ([table 1](#), online supplemental table S2 and [figure 2](#) for CMR illustration). Fourteen (48%) patients underwent coronarography for initial alternative diagnosis. EMB was obtained in six patients and showed lymphocyte infiltration in five of them, all with prominent T CD8 cells, and PD(L)-1 expression. Among associated toxicities, there was a median of two other irAE (range: 0–5), with the most frequent being musculoskeletal myositis (13 of 29, 45%). Eleven patients (38%) had sicca syndrome, including two cases fulfilling Sjögren's syndrome criteria.

Twenty-six patients were screened for autoantibodies at the time of myocarditis occurrence, 10 (38%) revealing antinuclear antibodies (ANA), including two patients who had pre-existing ANA. Specific autoantibodies included anti-myocardium in one patient, anti-acetylcholine receptor autoantibodies (AChRab) in 5 out of 15 patients

**Table 1** Description of 29 patients with ICI-induced myocarditis according to the classification by Bonaca *et al*<sup>9</sup>

Characteristics	Total (n=29)	Definite (n=12)	Probable (n=10)	Possible (n=7)
Male	<b>20 (69)</b>	7 (58)	8 (80)	5 (71)
Age—median (range), years	<b>69 (33–84)</b>	68 (33–84)	69 (54–80)	72 (53–83)
History of autoimmunity				
Definite disease	<b>9 (31)</b>	5 (42)	3 (30)	1 (14)
Auto-antibodies alone	<b>4 (14)</b>	0	2 (20)	2 (29)
Type of cancer				
Lung carcinoma	<b>10 (34)</b>	5 (42)	3 (30)	2 (29)
Melanoma	<b>8 (28)</b>	2 (16)	5 (50)	1 (14)
Others*	<b>11 (38)</b>	5 (42)	2 (20)	4 (57)
Metastatic	<b>24 (83)</b>	10 (83)	8 (80)	6 (86)
Previous cancer treatment				
Radiotherapy	<b>12 (42)</b>	6 (50)	3 (30)	3 (43)
Chemotherapy	<b>8 (28)</b>	5 (42)	1 (10)	2 (29)
Targeted therapy†	<b>6 (21)</b>	3 (25)	3 (30)	0 (0)
Type of ICI				
Anti-PD(L)-1	<b>19 (66)</b>	8 (67)	7 (70)	4 (57)
Combi-therapy	<b>10 (35)</b>	4 (33)	3 (30)	3 (43)
Time to myocarditis—median (range), days	<b>39 (2–181)</b>	33.5 (15–126)	56.5 (2–181)	44 (16–63)
Cardiac clinical symptoms‡	<b>24 (83)</b>	12 (100)	8 (80)	4 (57)
HS-troponin fold increase—median (range), UPL	<b>5.35 (1.57–456)</b>	6 (1.86–456)	2.89 (1.57–91.6)	25.7 (1.71–56.5)
Abnormal ECG	<b>20 (69)</b>	9 (75)	6 (60)	5 (71)
Abnormal TTE	<b>14/27 (52)</b>	6 (50)	6/9 (67)	2/6 (33)
Abnormal CMR suggestive of myocarditis	<b>18/25 (72)</b>	9/11 (82)	7/8 (87,5)	2/6 (33)
Modified Lake Louise criteria fulfilled	<b>10/25 (40)</b>	6 (50)	4 (40)	0 (0)
Myocarditis severity				
Severe	<b>11 (38)</b>	7 (58)	2 (20)	2 (29)
Clinically significant	<b>14 (48)</b>	5 (42)	6 (60)	3 (42)
Smoldering	<b>4 (14)</b>	0 (0)	2 (20)	2 (29)
Treatment modalities				
Glucocorticoids	<b>28 (97)</b>	12 (100)	10 (100)	6 (86)
Plasmapheresis	<b>10 (34)</b>	4 (33)	2 (20)	4 (57)
IVIg	<b>8 (28)</b>	2 (17)	2 (20)	4 (57)
Other immunosuppressants§	<b>5 (17)</b>	1 (8)	2 (20)	2 (29)
Follow-up—median (range), days	<b>123 (19–832)</b>	133 (8–832)	200 (49–830)	183 (22–333)
Deaths	<b>7 (24)</b>	4 (33)	1 (10)	2 (29)

Continued


**Table 1** Continued

Characteristics	Total (n=29)	Definite (n=12)	Probable (n=10)	Possible (n=7)
Data are shown as n (%) unless further specified. No statistical difference was found between groups.				
*Renal/bladder carcinoma (4), hepatocellular carcinoma (3), cholangiocarcinoma (1), cutaneous squamous cell carcinoma (1), gastric adenocarcinoma (1), mesothelioma (1).				
†Regorafenib, sorafenib, pazopanib, everolimus, sunitinib, cabozantinib, nintedanib, bevacizumab.				
‡Dyspnea, chest pain, lower limbs edema, palpitations.				
§Methotrexate (3), mycophenolate mofetil (1), ciclosporin (1).				
CMR, cardiac magnetic resonance; HS, high-sensitivity; ICI, immune checkpoint inhibitor; IVIg, intravenous immunoglobulins; PD(L)-1, programmed-cell death (ligand)-1; TTE, transthoracic echocardiography; UPL, upper limit.				

tested (all presenting myasthenia gravis (MG) symptoms), anti-striated muscle in two patients, anti-PL7 and anti-Scl70 for one patient each.

When we compared the most severe patients (n=11) versus non-severe patients (n=18) (table 2), they presented more pre-existent systemic autoimmune disease (45% vs 6%, p=0.018), lower exposure to anti-vascular endothelial growth factor (VEGF) (0/11 vs 7/18, p=0.025), higher heart rate (median of 113/min vs 79.5/min, p=0.001), more conduction trouble on ECG (45% vs 6%, p=0.018), a higher incidence of AChRAb positivity (5/6 vs 0/9, p=0.001), and higher troponin levels on admission (median of 42-fold the upper limit vs 3.55-fold, p=0.001). There was no difference between the two groups in terms of age, renal clearance, creatine kinase and C-reactive protein levels. Concerning troponin values among these two groups, the ROC analysis showed an area under curve (AUC) of 0.84 (95% CI: 0.69 to 0.98, p=0.002) (figure 3). When choosing a cut-off value of 4.89-fold the laboratory upper limit, we found a sensitivity of 90.9% and a specificity of 66.7%, with a likelihood ratio of 2.727.


Concerning myocarditis management (table 1), almost all patients (28 of 29, 97%) received glucocorticoids, mainly with initial intravenous pulses of 500–1000 mg (19 of 28, 68%). Other modalities of treatment included plasmapheresis, intravenous immunoglobulins, and immunosuppressants, with seven patients receiving combined treatments beyond glucocorticoids. Ten patients were admitted in the resuscitation ward, and six were admitted in cardiac intensive care unit.



**Figure 1** Time from immune checkpoint inhibitor initiation to myocarditis occurrence (days, median, IQR and min–max).

An assessment of cancer response at the time of myocarditis occurrence was available for 21 patients, with only 1 patient exhibiting disease progression, others presenting partial response (13 of 21, 61%), complete response (6 of 21, 29%), or stable disease (1 patient). We had a median treatment-free interval of 3.4 (range: 0–22) months, with a median follow-up of 4 (range: 0–28, IQR=8.6) months. Throughout the follow-up, eight additional patients died of cancer progression.

Six patients (four initially treated with combi-therapy) underwent rechallenge with an ICI in monotherapy (table 3). Initial myocarditis was classified as possible in three, probable in two, and definite in one (the latter with severe presentation, the other considered as clinically significant). After rechallenge, and a median follow-up of 566 (183–830) days, only one patient (first classified as CTCAE grade 3 possible myocarditis) suffered from grade 3 myocarditis relapse requiring ICI discontinuation



**Figure 2** Cardiac MRI demonstrating myocardial inflammation in a 33-year-old woman. (A) Short-axis-native T1 map showing elevated signal (1246±108 ms) consistent with hyperemia and/or fibrosis. (B) Vertical-long-axis Short Tau Inversion Recovery (STIR) image showing midventricular and basal edema. (C, D) Short-axis late enhancement images showing subepicardial late gadolinium enhancement consistent with fibrosis and necrosis in mid and basal left ventricular cardiac wall.




**Table 2** Comparison between severe patients versus non-severe patients

Characteristics	Severe patients (n=11)	Non-severe patients (n=18)	P value
Age—median, years	68	68.5	0.321
Previous autoimmune disease			
All	5 (45)	4 (22)	0.237
Systemic	5 (45)	1 (6)	<b>0.018</b>
Previous cancer treatments			
Radiotherapy	6 (55)	8 (44)	0.710
Anti-VEGF	0	7 (39)	<b>0.025</b>
Chemotherapy	4 (36)	4 (22)	0.432
Combi-therapy	1 (9)	9 (50)	<b>0.043</b>
Clinical features			
Heart rate, bpm	113	79,5	<b>0.001</b>
Median blood pressure, mm Hg	105	104	0.889
Biologic features			
Troponin—median, UPL	42	3,55	<b>0.001</b>
Elevated BNP	6/8 (75)	11/18 (61)	0.667
Conduction trouble on ECG	5 (45)	1/17 (6)	<b>0.022</b>
TTE LVEF <50%	4/10 (40)	6/17 (35)	1
Associated toxicities			
Myositis	6 (55)	6 (33)	0.438
Sicca syndrome	3 (27)	8 (44)	0.448
AChRAb	5/6 (83)	0/9	<b>0.001</b>
Treatment-free interval—median, months	6.7	2.9	0.428

Data are shown as n (%) unless specified. Severity was defined according to the IC-OS consensus statement by Hermann *et al.*<sup>8</sup> Quantitative variables were compared using Mann-Whitney non-parametric tests, and qualitative variables were compared with Fisher's exact test. P values that reached significance appear in bold.

AChRAb, acetylcholine receptor antibodies; BNP, brain natriuretic peptide; IC-OS, International Cardio-Oncology Society; LVEF, left ventricular ejection fraction; TTE, transthoracic echocardiography; UPL, upper limit; VEGF, vascular endothelial growth factor.


**Figure 3** Receiver operating characteristic curve for admission troponin between severe and non-severe patients.

and glucocorticoids, and eventually died of cancer progression.

## DISCUSSION

Here we reported on a novel series of 29 cases of myocarditis in patients treated by ICI, with a lower mortality rate than initially described.<sup>6</sup> This may stem from earlier detection using systematic screening on ECG and troponin, as recently reported.<sup>11 12</sup>

If EMB is considered as the gold-standard technique for myocarditis diagnosis, it may be difficult to proceed outside referral centers, it is not free of adverse events, and may be false negative. In five of our patients, EMB showed pre-eminent CD8 T-lymphocyte infiltration within the myocardium, like cellular rejection following heart transplantation. The latter patient did not have lymphocytic infiltration, although it may be important to bear in mind that 10–20% of cardiac allograft rejection are biopsy-negative.<sup>13</sup> In the absence of histology, new CMR procedures such as T1-mapping or T2-mapping seem promising.<sup>14</sup>

One challenge in this analysis is the assessment of myocarditis severity, since clinical presentation may vary from smoldering to fulminant events.<sup>5 15</sup> We found some prognostic factors, such as higher heart rate and troponin values on admission, that were correlated with severity (according to the recent definition of the IC-OS<sup>8</sup> or by CTCAE classification grade 4–5), congruent with literature.<sup>16</sup> We also found in the most severe group a higher proportion of pre-existing systemic autoimmune disease, patients that had been first excluded from clinical trials, but now treated when the benefit/risk balance seems positive. In the same way, our findings confirm that AChRAb positivity is related to the severity of myocarditis, which was previously described ('3M syndrome': MG

**Table 3** Outcome of the six patients ICI-rechallenged after myocarditis occurrence

Sex / age	Cancer	Initial ICI	Myocarditis			Diagnosis	Severity	Treatment	ICI rechallenge		Outcome after ICI rechallenge		Death*		
			Bonaca	Time to onset (d)	Bonaca				Time (d)	ICI	Myocarditis relapse	New irAEs		TTP up (d)	Follow-up (d)
1 M / 54	Melanoma	CTLA-4+PD-1	Pro	63	Pro	Elevation of troponin + clinical syndrome + ECG + decline in systolic function	Clinically significant	GC	112	PD-1	-	-	720	830	0
2 M / 71	NSCLC	PD-1	Def	64	Def	Pathology	Severe	GC	14	PD-1	-	-	180	325	1
3 F / 53	Melanoma	CTLA-4+PD-1	Pos	46	Pos	Elevation of troponin + clinical syndrome + concomitant myositis	Clinically significant	GC; IVIg; MTX; PLEX	140	PD-1	-	-	90	288	1
4 F / 69	Melanoma	CTLA-4+PD-1	Pos	21	Pos	Elevation of troponin + clinical syndrome + ECG + negative angiography	Clinically significant	GC	42	PD-1	-	-	45	807	0
5 M / 71	Melanoma	CTLA-4+PD-1	Pro	39	Pro	Elevation of troponin + clinical syndrome + ECG + elevated T2m on CMR	Clinically significant	GC	28	PD-1	-	-	56	811	0
6 M / 72	NSCLC	PD-1	Pos	58	Pos	Elevation of troponin + clinical syndrome + ECG + negative angiography	Clinically significant	-	150	PD-1	†	-	28	183	1

\*All deaths were caused by cancer progression.

†Clinically significant, treated with glucocorticoids with favorable outcome.

CMR, cardiac magnetic resonance; CTLA-4, cytotoxic T-lymphocyte-associated antigen-4; d, days; Def, definite; GC, glucocorticoids; ICI, immune checkpoint inhibitor; irAEs, immune-related adverse events; IVIg, intravenous immunoglobulins; MTX, methotrexate; NSCLC, non-small-cell lung cancer; PD-1, programmed-death 1; PLEX, plasma exchange; Pos, possible; Pro, probable; TTP, time to progression.

associated with myocarditis and myositis).<sup>6,17</sup> Concerning associated toxicities, Sjögren-like syndromes under ICI have been described before, and the onset of sicca syndrome in patients treated with ICI may be a signal for multi-toxicity or severe toxicities.<sup>18</sup> We did not find any correlation either between combi-therapy and myocarditis severity, or with shorter delay for myocarditis (35 days vs 43 for monotherapy,  $p=0.232$ ), although literature seems to identify higher fatality rate during ICI combi-therapy.<sup>6</sup> However, this discrepancy may be linked with the strengthened monitoring of patients under combi-therapy. Unexpectedly, patients previously treated with anti-VEGF were more frequently in the non-severe group, suggesting an unintuitive protective role, although VEGF have been identified to have immunomodulatory effect by reducing CD8 recruitment.<sup>19</sup> Ongoing studies with VEGF-directed therapies and ICI should be examined to validate—or not—the protective role seen in this case series.

Concerning myocarditis management itself, some patients underwent plasma exchanges (four severe cases and six non-severe cases). We did not find any significant difference in outcomes in terms of cardiac function or troponin measurements (data not shown), but we demonstrate the feasibility of this approach. Although studies have to be conducted, we may suggest to propose early plasmapheresis on a case-by-case basis in patients who may be considered at risk for grade 4–5 myocarditis (ie, previous autoimmunity, high troponin level, concomitant myositis or MG). Plasma exchange may also aim at withdrawing the monoclonal antibody when myocarditis occurrence is close to the last infusion. Herein, admission troponin cut-off value of 4.89-fold the upper limit may be used as an early screening tool. It emphasizes the need for early management, supported by a trained network.

Eventually, once the irAE is efficiently managed, current guidelines recommend definitive contraindication if the grade is  $\geq 2^4$ , which is quite always the case. However, immunotherapy may be the last option for these patients, leading to a predicament. Detection of smoldering presentations of myocarditis with better outcome outlines the need to reconsider definitive contraindication especially in those that had been first treated by combi-therapy. A pharmacovigilance study found a recurrence rate of 28.8% of the same irAE after ICI rechallenge,<sup>7</sup> with no relapse for the three myocarditis cases described, and only one in our series. In our study, rechallenge was also associated with further oncological response although half of the patients finally died from cancer progression with a median follow-up of 566 days.

There are some limitations to our work, mainly the retrospective and declarative design. CMR was performed locally, with heterogeneous protocols. Half of our patients did not undergo coronarography, and EMB was performed in only six of them, while reflecting a real life framework with often unstable patients.

## CONCLUSION

Myocarditis may exhibit various clinical presentations from smoldering to fulminant forms. We found that life-threatening events more frequently occurred in patients with underlying autoimmunity and were associated with a higher heart rate and troponin level at admission, and the presence of anti-acetylcholine receptor autoantibodies. Apart from ICI discontinuation and early steroid administration, plasma exchanges are feasible in this context, while their benefits remain to be demonstrated. In smoldering myocarditis with initial favorable course, ICI rechallenge may be considered after an accurate evaluation of the benefit/risk balance. Further studies are needed to evaluate the value of troponin follow-up, specific risk factors and assess the benefit/risk balance of ICI rechallenge.

## Author affiliations

<sup>1</sup>Department of Internal Medicine, CHRU de Montpellier, Montpellier, France

<sup>2</sup>Department of Radiology, CHRU de Montpellier, Montpellier, France

<sup>3</sup>Department of thoracic oncology, Regional Cancer Centre Val d'Aurelle - Paul Lamarque, Montpellier, France

<sup>4</sup>Department of Dermatology, CHRU de Montpellier, Montpellier, France

<sup>5</sup>Gustave Roussy Institute, Villejuif, France

<sup>6</sup>Gustave Roussy, Villejuif, France

<sup>7</sup>Cardiology, Assistance Publique - Hôpitaux de Paris, Paris, France

<sup>8</sup>Department of Oncology, CHRU de Montpellier, Montpellier, France

<sup>9</sup>Department of Interventional Cardiology, CHU de Bordeaux Hôpital Cardiologique, Pessac, France

<sup>10</sup>Intensive Care Unit, CHU de Bordeaux, Bordeaux, France

<sup>11</sup>Department of Internal Medicine, CHU Bicêtre, Le Kremlin-Bicêtre, France

<sup>12</sup>Médecine Interne et Maladies Infectieuses, Centre Hospitalier Universitaire de Poitiers, Poitiers, France

<sup>13</sup>CIC-1402, Centre Hospitalier Universitaire de Poitiers, Poitiers, France

<sup>14</sup>Medical Oncology Department, Institut régional du Cancer de Montpellier, Montpellier, France

<sup>15</sup>Department of Pathology, CHRU de Montpellier, Montpellier, France

<sup>16</sup>Department of Intensive Care Medicine, CHRU de Montpellier, Montpellier, France

<sup>17</sup>Department of Anesthesiology and Critical Care Medicine, CHRU de Montpellier, Montpellier, France

<sup>18</sup>Department of Medical Pharmacology and Toxicology, University Hospital Centre Montpellier, Montpellier, France

<sup>19</sup>Department of Cardiology, CHRU de Montpellier, Montpellier, France

<sup>20</sup>U1183, Institut national de la santé et de la recherche médicale, Paris, France

**Twitter** Jean-Luc Faillie @jlfaille

**Acknowledgements** We thank Sylvie Modurier for proofreading the manuscript.

**Contributors** CC: Conceptualization, Methodology, Formal Analysis, Investigation, Writing—Original Draft. XQ: Resources, Writing—Review and Editing. CL: Resources, Writing—Review and Editing. J-MM: Conceptualization, Resources, Writing—Review and Editing. AL: Resources. SE: Writing—Review and Editing. EA: Resources, Writing—Review and Editing. MF: Writing—Review and Editing. NI: Resources. OL: Resources, Writing—Review and Editing. MP: Resources, Writing—Review and Editing. OD: Resources. DT: Resources. PR: Resources. IS: Investigation. RL: Resources. KK: Resources, Writing—Review and Editing. GC: Resources, Writing—Review and Editing. JV: Resources, Investigation, Formal Analysis, Review and Editing. HV-K: Investigation. J-LF: Writing—Review and Editing. AA: Investigation. FR: Resources, Investigation, Writing—Review and Editing, Supervision. PG: Methodology, Writing—Review and Editing, Project administration. AM: Conceptualization, Methodology, Formal analysis, Writing—Review and Editing. CC is the guarantor of the work, and as such takes full responsibility for the work and/or the conduct of the study, had access to the data, and controlled the decision to publish.

**Funding** The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.



**Competing interests** AM has received fees from AbbVie, Actelion, CSL Behring, Experif, Novartis, and Shire and declares speaking fees from AstraZeneca, Sanofi-Aventis and BMS in the last 5 years. PG is a medical expert for LFB (Laboratoire Français du Biofractionnement) and has received fees from AbbVie, Actelion, Boehringer Ingelheim France, Bouchara-Recordati, Novartis, Pfizer, and Roche in the last 5 years. Other authors declare that they have no conflicts of interest.

**Patient consent for publication** Not applicable.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data availability statement** Data are available upon reasonable request.

**Supplemental material** This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See <http://creativecommons.org/licenses/by-nc/4.0/>.

#### ORCID iDs

Stephane Ederhy <http://orcid.org/0000-0002-0792-2521>

Mathieu Puyade <http://orcid.org/0000-0002-5639-0138>

Jean-Luc Faillie <http://orcid.org/0000-0003-0100-4073>

Alexandre Thibault Jacques Maria <http://orcid.org/0000-0002-0868-5804>

#### REFERENCES

- Tang J, Shalabi A, Hubbard-Lucey VM. Comprehensive analysis of the clinical immuno-oncology landscape. *Ann Oncol* 2018;29:84–91.
- Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus Docetaxel in advanced squamous-cell non-small-cell lung cancer. *N Engl J Med* 2015;373:1627–39.
- Longo DL, Postow MA, Sidlow R, et al. Immune-related adverse events associated with immune checkpoint blockade. *N Engl J Med* 2018;378:158–68.
- Haanen J, Carbonnel F, Robert C, et al. Management of toxicities from Immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2017;28:iv119–42.
- Johnson DB, Balko JM, Compton ML, et al. Fulminant myocarditis with combination immune checkpoint blockade. *N Engl J Med* 2016;375:1749–55.
- Salem J-E, Manouchehri A, Moey M, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, Pharmacovigilance study. *Lancet Oncol* 2018;19:1579–89.
- Dolladille C, Da-Silva A, Alexandre J. Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer. *JAMA Oncol* 2020;6:1814–5.
- Herrmann J, Lenihan D, Armenian S, et al. Defining cardiovascular toxicities of cancer therapies: an international Cardio-oncology society (IC-OS) consensus statement. *Eur Heart J* 2022;43:280–99.
- Bonaca MP, Olenchock BA, Salem J-E, et al. Myocarditis in the setting of cancer therapeutics: proposed case definitions for emerging clinical syndromes in Cardio-oncology. *Circulation* 2019;140:80–91.
- Ferreira VM, Schulz-Menger J, Holmvang G, et al. Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations. *J Am Coll Cardiol* 2018;72:3158–76.
- Cautela J, Zerriouh S, Gaubert M, et al. Intensified immunosuppressive therapy in patients with immune checkpoint inhibitor-induced myocarditis. *J Immunother Cancer* 2020;8:e001887.
- Zhang L, Zlotoff DA, Awadalla M, et al. Major adverse cardiovascular events and the timing and dose of corticosteroids in immune checkpoint inhibitor-associated myocarditis. *Circulation* 2020;141:2031–4.
- Fishbein MC, Kobashigawa J. Biopsy-negative cardiac transplant rejection: Etiology, diagnosis, and therapy. *Curr Opin Cardiol* 2004;19:166–9.
- Zhang L, Awadalla M, Mahmood SS, et al. Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis. *Eur Heart J* 2020;41:1733–43.
- Norwood TG, Westbrook BC, Johnson DB, et al. Smoldering myocarditis following immune checkpoint blockade. *J Immunother Cancer* 2017;5:91.
- Mahmood SS, Fradley MG, Cohen JV, et al. Myocarditis in patients treated with immune checkpoint inhibitors. *J Am Coll Cardiol* 2018;71:1755–64.
- Anquetil C, Salem J-E, Lebrun-Vignes B, et al. Immune checkpoint inhibitor-associated Myositis: expanding the spectrum of cardiac complications of the Immunotherapy revolution. *Circulation* 2018;138:743–5.
- Ramos-Casals M, Maria A, Suárez-Almazor ME, et al. Sicca/Sjögren's syndrome triggered by PD-1/PD-L1 checkpoint inhibitors. Data from the International Immunocancer Registry (ICIR). *Clin Exp Rheumatol* 2019;37 Suppl 118:114–22.
- Nykänen AI, Sandelin H, Krebs R, et al. Targeting Lymphatic vessel activation and CCL21 production by vascular endothelial growth factor Receptor-3 inhibition has novel immunomodulatory and Antiarteriosclerotic effects in cardiac Allografts. *Circulation* 2010;121:1413–22.